Literature DB >> 30881603

Evaluation of drug combination effect using a Bliss independence dose-response surface model.

Qin Liu1, Xiangfan Yin1, Lucia R Languino2, Dario C Altieri3.   

Abstract

To test the anticancer effect of combining two drugs targeting different biological pathways, the popular way to show synergistic effect of drug combination is a heat map or surface plot based on the percent excess the Bliss prediction using the average response measures at each combination dose. Such graphs, however, are inefficient in the drug screening process and it doesn't give a statistical inference on synergistic effect. To make a statistically rigorous and robust conclusion for drug combination effect, we present a two-stage Bliss independence response surface model to estimate an overall interaction index (τ) with 95% confidence interval (CI). By taking into all data points account, the overall τ with 95% CI can be applied to determine if the drug combination effect is synergistic overall. Using some example data, the two-stage model was compared to a couple of classic models following Bliss rule. The data analysis results obtained from our model reflect the pattern shown from other models. The application of overall τ helps investigators to make decision easier and accelerate the preclinical drug screening.

Entities:  

Keywords:  Bliss independence; drug combination; interaction index; synergistic effect

Year:  2018        PMID: 30881603      PMCID: PMC6415926          DOI: 10.1080/19466315.2018.1437071

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  28 in total

1.  Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL.

Authors:  Doina Atanasiu; Wan Ting Saw; Tina M Cairns; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

2.  Efficient Measurement of Drug Interactions with DiaMOND (Diagonal Measurement of N-Way Drug Interactions).

Authors:  Nhi Van; Yonatan N Degefu; Bree B Aldridge
Journal:  Methods Mol Biol       Date:  2021

3.  Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.

Authors:  Majid Momeny; Zivar Alishahi; Haniyeh Eyvani; Fatemeh Esmaeili; Azam Zaghal; Parisa Ghaffari; Javad Tavakkoly-Bazzaz; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-09-06       Impact factor: 6.730

4.  Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers.

Authors:  Joseph A Zundell; Takeshi Fukumoto; Jianhuang Lin; Nail Fatkhudinov; Timothy Nacarelli; Andrew V Kossenkov; Qin Liu; Joel Cassel; Chih-Chi Andrew Hu; Shuai Wu; Rugang Zhang
Journal:  Cancer Res       Date:  2021-09-21       Impact factor: 13.312

5.  PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model.

Authors:  Masayuki Fujino; Xiao-Kang Li; Xin Hu; Yifang Shui; Hiroshi Hirano; Kisato Kusano; Wen-Zhi Guo
Journal:  Cancer Immunol Immunother       Date:  2022-09-02       Impact factor: 6.630

6.  Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.

Authors:  Christian Setz; Maximilian Große; Janina Auth; Maria Fröba; Pia Rauch; Alexander Bausch; Matthew Wright; Ulrich Schubert
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

7.  HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.

Authors:  Joshua L D Parris; Thibaut Barnoud; Julia I-Ju Leu; Jessica C Leung; Weili Ma; Nicole A Kirven; Adi Naryana Reddy Poli; Andrew V Kossenkov; Qin Liu; Joseph M Salvino; Donna L George; Ashani T Weeraratna; Qing Chen; Maureen E Murphy
Journal:  Cancer Res Commun       Date:  2021-10

8.  Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle-mediated trafficking.

Authors:  Miao Zhao; Fan Zhang; Robert Zarnowski; Kenneth Barns; Ryley Jones; Jen Fossen; Hiram Sanchez; Scott R Rajski; Anjon Audhya; Tim S Bugni; David R Andes
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

9.  Antifungal activity of Acylhydrazone derivatives against Sporothrix spp.

Authors:  Jhon Jhamilton Artunduaga Bonilla; Leandro Honorato; Krupanandan Haranahalli; Isabella Dib Ferreira Gremião; Sandro Antonio Pereira; Allan Guimarães; Andrea Regina de Souza Baptista; Patricia de M Tavares; Marcio L Rodrigues; Kildare Miranda; Iwao Ojima; Maurizio Del Poeta; Leonardo Nimrichter
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.938

10.  PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.

Authors:  Cheng Wu; Shan Peng; Patrick G Pilié; Chuandong Geng; Sanghee Park; Ganiraju C Manyam; Yungang Lu; Guang Yang; Zhe Tang; Shakuntala Kondraganti; Daoqi Wang; Courtney W Hudgens; Debora A Ledesma; Mario L Marques-Piubelli; Carlos A Torres-Cabala; Jonathan L Curry; Patricia Troncoso; Paul G Corn; Bradley M Broom; Timothy C Thompson
Journal:  Mol Cancer Ther       Date:  2021-06-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.